Albumedix Media News & Events Cell & Gene Manufacturing and Commercialization USA

Cell & Gene Manufacturing and Commercialization USA

19 Sep 2023

Albumedix, now a part of Sartorius, will showcase the Recombumin® recombinant human albumin portfolio at the Cell and Gene Therapy Manufacturing and Commercialization Conference September 19-21, 2023


The cell and gene therapy event for ground-breaking manufacturing, commercialization, and supply chain strategies where World renowned leaders share the latest bioprocessing science and technologies to improve manufacturing scalability, cost, and quality to increase access to patients in rare diseases and beyond. Speak to our team about how Recombumin could improve your pharmaceutical at the event, or get in touch today.

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven company and recognized leader of best-in-class albumin-enabled solutions. Established in the UK in 1984, with a mission to empower excellence, Albumedix has supported its life-science partners to deliver hundreds of million safe doses of clinical and marketed therapeutics, globally. Albumedix’ solutions include the world’s only USP-NF compliant recombinant human albumin (Recombumin®), client-centric development and compliance services and drug-enhancing technologies (Veltis®). By always striving for more and collaboratively challenging status quo, Albumedix enables the development and commercialisation of advanced therapies and next-generation biopharmaceuticals to the benefit of people worldwide.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US